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wound repair; horse model; THBS2; SPARC; angiogenesis WOUNDS ON HORSE LIMBS OFTEN develop exuberant granulation tissue (EGT), a highly vascular tissue that behaves clinically like a benign tumor and resembles the human keloid, in that the evolving scar is trapped in the proliferative phase of repair, leading to fibrosis (19, 20) . This condition generates extensive scarring that may adversely affect form and function. While loss of conformation is detrimental to show horses, the impact on racehorses is also significant since roughly 7% of injuries leading to their retirement are the direct result of a wound (33) .
Several mechanisms have been incriminated in problematic wound repair in horses including an inefficient inflammatory response to trauma (43, 44) , persistent local upregulation of profibrotic cytokines (39, 29) , a disparity between collagen synthesis and lysis (36) , as well as microvascular occlusion and deficient apoptosis of the cellular components of granulation tissue (28) . These irregularities are limited to wounds located on the limb; even extensive wounds of the trunk and head usually heal uneventfully (19, 20, 43) . Attempts to ameliorate the repair of chronic wounds and prevent the development of EGT/keloids in the horse have been disappointing. This may relate to deficient knowledge of the underlying molecular mechanisms.
Dermal wound repair involves sophisticated interactions between cells, cytokines, and extracellular matrix (ECM) components acting locally and in parallel with numerous systemic factors. Transition between the phases of repair depends on the activation and/or silencing of many genes such that a disturbance in gene expression can lead to abnormal scarring. A handful of studies have analyzed the expression of specific genes during normal or impaired healing (8, 37) , though only one has been performed in the horse (36) . Given the complexity of the repair process, we recently undertook a comprehensive study in an effort to identify the genes differentially expressed during normal wound repair in the horse (27) . mRNA expression profiling of the proliferative phase of repair of normally healing body wounds revealed 226 nonredundant, differentially expressed cDNAs. In the study described herein, we have targeted two cDNA fragments corresponding to equine thrombospondin II (THBS2) and secreted protein acidic and rich in cysteine (SPARC) for their potential contribution to angiogenesis, a major component of EGT (31) . While THBS1 is also known as an endogenous inhibitor of wound healingassociated angiogenesis (38) , it was not differentially expressed in our previous model of wound repair in the horse (27) and thus not studied herein.
Matricellular proteins form a group of ECM proteins that, via simultaneous binding to other matrix proteins, cell surface receptors, and molecules such as proteinases and cytokines, modulate cell-matrix interactions. The glycoproteins THBS2 and SPARC are members of this group (24) and are known to participate in a number of processes related to tissue repair. THBS2 exhibits potent antiangiogenic activities (24) , can modulate the levels of matrix metalloproteinases (MMP)s, and participates in the regulation of collagen fibrillogenesis (22) . SPARC expression is restricted to tissues that undergo consistent turnover or to sites of injury and disease (6) . It is postulated to modulate cell shape and adhesion, to regulate cell proliferation and migration, and to influence matrix contraction. In vitro, SPARC has antiangiogenic properties, including the ability to inhibit the proliferation and migration of endothelial cells stimulated by basic fibroblast growth factor (bFGF) (17) and vascular endothelial growth factor (VEGF) (21) . Likewise, SPARC's negative influence on in vivo tumor growth (12) in various types of cancer has been attributed to a decrease in angiogenesis via interference with the VEGF/ VEGF-receptor 1 signaling pathway (11, 47) . In addition, SPARC is known to bind certain cytokines thus altering their efficacy and to affect the expression of MMPs, all functions indispensable to wound repair (6) .
We hypothesized that the temporal pattern of expression of these genes with potential roles in angiogenesis would differ between healing body and limb wounds in horses. The specific objectives of this study were to clone full-length equine THBS2 and SPARC cDNAs from skin wounds and to study the spatiotemporal profile of expression of these mRNAs and proteins during the repair of body and limb wounds in horses. The ultimate objective of our research program is to contribute to a better understanding of the repair process and permit the development of novel strategies to resolve wound healing complications.
METHODOLOGY
Characterization of equine THBS2 and SPARC cDNA. Isolation of the full-length equine cDNAs was performed by screening sizeselected cDNA libraries. Initially, the size of the full-length equine cDNAs was estimated for each gene by performing virtual Northern blot analyses. Briefly, total RNA was isolated from a biopsy specimen obtained from the wound edge 7 days following creation of a square, 6.25 cm 2 full-thickness wound on the lateral thoracic wall (27) , and reverse-transcribed into cDNA by the SMART cDNA synthesis method (BD Biosciences Clontech, Mississauga, ON, Canada) as described (29) . The cDNAs were separated by gel electrophoresis, transferred onto a nylon membrane, and hybridized with equine radioactive probes (THBS2 ϭ 453 bp; SPARC ϭ 334 bp) generated from a previous experiment (27) . On the basis of the hybridized cDNA band of highest molecular weight, size-specific libraries were established via the pDrive plasmid cloning technique (Qiagen PCR cloning kit, Qiagen) and screened by radioactive hybridization as described (29) . Positive hybridizing bacterial colonies were grown, their plasmid contents were isolated (QIA-prep, Qiagen), and the size of the cloned cDNA was analyzed via gel electrophoresis analysis following EcoR1 digestion. The cDNAs were sequenced via the dideoxy sequencing method (Big Dye Terminator 3.0; ABI Prism, Applied BioSystems, Branchburg, NJ) and analyzed on an ABI Prism 310 sequencer (Applied BioSystems). Nucleic acid sequences were analyzed by Basic Local Alignment Search Tool (BLAST) and protein sequences deduced from cDNAs were analyzed by PSI-and PHI-BLAST (www.ncbi.nlm.nih.gov/BLAST/) against GenBank data banks.
Equine tissues and RNA extraction. Thoracic and limb normal skin as well as wound edge biopsy specimens were taken at specific times during the repair process from four normal, 2-to 3-yr-old Standardbred mares, as described (28) . Briefly, five square, 6.25 cm 2 areas were excised on the dorso-lateral surface of one randomly assigned metacarpus beginning just above the fetlock, and on the lateral thoracic wall, 1.5 cm apart in a staggered vertical column, then left to heal by second intention. Excised skin from the lowermost wound was kept as a time 0 sample. One wound per site (thorax; limb) was sampled at the following times in each horse: 1, 2, 3, 4, and 6 wk. To avoid repeated trauma, each wound, beginning with the most distal one, was designated for a single biopsy. Full-thickness specimens were taken with an 8-mm-diameter biopsy punch to include a 3-to 4-mm strip of peripheral skin, the migrating epithelium and a 3-to 4-mm strip of granulation tissue from the wound center, when present. Tissues were snap-frozen in liquid nitrogen and stored at Ϫ80°C. Total RNA from all samples was extracted and analyzed as described (3) . Experiments were approved by the Animal Ethics Committee of the Faculty of Veterinary Medicine of the Université de Montréal and were sanctioned by the Canadian Council on Animal Care.
Semiquantitative RT-PCR analysis of temporal expression of mRNA. Total RNA was first reverse-transcribed into cDNA. We used 1 g of total RNA from samples of healing thoracic wounds (n ϭ 4 mares) for each biopsy time; the same was done for limb wound samples. RNA was reverse-transcribed with an oligo-dT30 primer and PowerScript (BD Biosciences Clontech) to generate the first-strand cDNA using the SMART PCR cDNA synthesis kit (User manual: PT3041-1; BD Biosciences Clontech) (32) . Second cDNA strands were produced and PCR-amplified using Advantage 2 DNA polymerase (BD Biosciences Clontech). To perform semiquantitative RT-PCR, SMART cDNAs were used in a 25 l PCR reaction with the Advantage 2 DNA polymerase kit (BD Biosciences Clontech). Gene-specific PCR primers were designed in the open reading frame (ORF) of the equine cDNA sequence for: THBS2 (sense: 5Ј-GACGGAGACGATGTCTTCAACG-3Ј; anti-sense: 5Ј-TCAGTGTTGACGTAAAACGTGC-3Ј; GenBank: DQ976362), SPARC (sense: 5Ј-ATGAGGGCCTGGATCTTCTTTCTC-3Ј; anti-sense: 5Ј-GTTAGATCACCAGGTCCTTGTCG-3Ј; GenBank: DQ521572) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH; sense: 5Ј-CAAGT-TCCATGGCACAGTCACGG-3Ј; anti-sense: 5Ј-AAAGTGGTCGTT-GAGGGCAATGC-3Ј) (17) .
For all samples, PCR was performed in triplicate by Mastercycler ep. The number of cycles used was optimized for each gene to fall within the linear range of PCR amplification: GAPDH ϭ 18 cycles, THBS2 ϭ 22 cycles, and SPARC ϭ 17 cycles. The PCR reactions (20 l/reaction) were resolved on a 2% TAE-agarose gel (40 mM Tris acetate, pH 8; 1 mM EDTA) with ethidium bromide (0.5 g/ml); PCR products were visualized by UV, and the images were digitized. The digitized signals for each gene were analyzed by densitometry using the National Institutes of Health Image program (http://rsb.info.nih.gov/nih-image/).
Immunoblot analyses. Samples of equine adrenal cortex and testis were homogenized in M-PER buffer (Pierce, Rockford, IL) supplemented with a mix of protease inhibitors (Complete; Roche Applied Science, Laval, QC, Canada) as recommended by the manufacturer. Tissues were homogenized at 7,000 rpm with a polytron homogenizer (model #PT1300D; Kinematica, Littau-Lucerne, Switzerland). The protein extracts were centrifuged at 10,000 g for 5 min at 4°C, and the recovered supernatant (whole cell extract) was stored at Ϫ80°C until electrophoretic analyses were performed. Protein concentration was determined by the Bradford method (5) (Bio-Rad Protein assay; Bio-Rad Laboratories, Hercules, CA). Protein extracts (100 g protein/sample) were heat-treated (5 min, 100°C) and size-fractionated via a one-dimensional SDS-PAGE, then electrophoretically transferred onto polyvinylidene difluoride membranes (PVDF; Hybond-P, Amersham Pharmacia Biotech).
Immunoblots were performed as described (9) . Membranes were incubated either with a rabbit anti-equine THBS2 polyclonal antibody (dilution 1:500; EZBiolab, Westfield, IN) or with the mouse antihuman SPARC MAb (dilution 1:1,000; MAB941; R&D Systems, Minneapolis, MN). As secondary antibodies, a donkey anti-rabbit IgG-HRP conjugated (dilution 1:15,000 NA934; Amersham Pharmacia Biotech) and a sheep anti-mouse IgG-HRP (dilution 1:10,000; NA931; Amersham Pharmacia Biotech) were used. The anti-THBS2 antibody (synthesized for this study by EZBiolab) was generated against a synthetic peptide ( 167 CDLIDSFTLDEPFYE 181 ) from a region where there is no amino acid homology between THBS1 and THBS2, to ensure against the possibility of cross-reactivity.
Detection of immunoreactive proteins was performed by the enhanced chemiluminescence system (ECL Plus, Amersham Pharmacia Biotech) following the manufacturer's protocol, and the proteins were exposed to Hyperfilm (Amersham Pharmacia Biotech). Autoradiographic images were digitized using a ScanMaker 9800XL flatbed scanner (Microtek lab, Redondo Beach, CA).
Immunohistochemical localization of THBS2 and SPARC. PBSbuffered formalin-fixed tissues were prepared as described (9, 14) . Paraffin-embedded tissues were cut to 3 m thickness, mounted on SuperfrostPlus slides (Fisher Scientific, Pittsburgh, PA), deparaffinized, and then rehydrated. Antigenicity lost during the fixation process was retrieved by heat treatment in a pressure cooker for 15 min (9, 14) . Nonspecific binding sites were saturated by 30 min incubation in blocking buffer: TBS (100 mM Tris, pH 7.5; 150 mM NaCl), 1% bovine serum albumin, and 1% fat-free skim milk (2, 9) . Tissue sections were incubated overnight at 4°C with the primary and secondary antibodies described above, diluted in the blocking buffer (THSB2 50 g/ml; SPARC 1:20). Negative control tissue sections were incubated similarly. After three 10-min washes in TBS, complexes were detected by incubation for 2 h at room temperature with a monoclonal anti-rabbit (A-2556, Sigma-Aldrich) or a polyclonal anti-mouse (A-1682, Sigma-Aldrich) IgG conjugated with alkaline phosphatase diluted to 1:100 or 1:50, respectively, in blocking buffer. Tissue sections were washed twice in TBS and once in TBS-MgCl 2 (100 mM Tris pH 9.5, 50 mM MgCl2) and incubated with the 4-nitro blue tetrazolium chloride/5-bromo-4-chloro-3-indolyl-phosphate alkaline phosphatase substrate (Roche Applied Science). Sections were mounted in Vectamount Permanent Mounting Medium (Vector Laboratories, Burlingame, CA). Reactivity was scored as negative (Ϫ), weak (ϩ), moderate (ϩϩ), or strong (ϩϩϩ) according to the staining intensity. Photographs were taken under bright field illumination using a Nikon Eclipse E400 microscope equipped with a digital camera (Nikon Coolpix 4500). Digital images were processed and assembled by Photoshop software (Adobe Systems, San Jose, CA).
Statistical analysis. Gene-specific signals (THBS2, SPARC) were normalized with corresponding GAPDH signals for each sample. A repeated-measures (RM) linear model, with site (thorax vs. limb) and sample time as within-subject factors, was used to determine the effects of site and time on gene expression. When the RM linear model indicated significant differences (P Ͻ 0.05), a priori contrasts were used to compare preselected individual means. All analyses were carried out with a P value Ͻ 0.05, using SAS v. 9.1 (Cary, NC).
RESULTS
Cloning and characterization of equine cDNA for THBS2 and SPARC. The cDNA fragments for THBS2 and SPARC used for the virtual Northern analyses originated from a gene expression profiling experiment aimed at identifying mRNAs that were increased or induced during the proliferative phase of wound repair in the horse (27) . The virtual Northern analyses determined the approximate molecular weights of the fulllength cDNAs of the genes targeted in this study. These cDNA fragments were also used as probes to screen, by hybridization, appropriate size-selected cDNA libraries generated from equine thoracic wound margin biopsy specimens collected 7 days postoperatively. The cDNA size-selected libraries each consisted of 1,536 bacterial colonies; hybridization identified three positive colonies each for THBS2 and SPARC. Two clones each were selected for plasmid DNA purification and sequencing.
Characterization of equine THBS2 cDNA showed that it consisted of 5,590 bp (DQ976362) that included an ORF of 3,516 bp coding for 1,172 amino acids, and a 3Ј-untranslated region (UTR) of 2,246 bp consisting of nine copies of an AU-rich element (ATTTA), in addition to five polyadenylation signals (AATAA) followed by a poly-A ϩ tail. The ORF coded for a protein of a theoretical molecular mass of 130 kDa with an isoelectric point (pI) of 4.42. Analysis of the protein sequence by SignalP software (13) revealed a signal peptide M 1-A 18 that should be cleaved to yield a mature protein of 128 kDa with a pI of 4.4. Amino acid homology search in GenBank revealed orthologous proteins with an overall identity level of 92, 91, and 88% for bovine, human, and mouse THSB2 proteins, respectively, indicating that THBS2's sequence is well conserved across species (Fig. 1) Temporal expression of THBS2 and SPARC mRNAs in wounds of the equine thorax and limb. The RM linear model confirmed a significant effect of site, across time (P ϭ 0.001) and of time, across sites (P Ͻ 0.0001) on the expression of THBS2 mRNA. The site effect varied from one time to another (P Ͻ 0.0001). Globally, THBS2 mRNA expression was superior in thoracic wounds; this difference was significant at weeks 1, 2, 3, and 6 of repair. Semiquantitative RT-PCR showed an induction of mRNA expression with a peak at week 2 in thoracic wounds; the peak in limb wounds occurred slightly later at 2 and 3 wk of repair. Expression returned to baseline in limb but not thoracic wounds by the end of the study (Fig. 2) .
SPARC mRNA was constitutively expressed in unwounded equine skin at both locations. The RM linear model unveiled a near significant effect of site across time (P ϭ 0.08) and a significant effect of time across sites (P Ͻ 0.0001). The effect of site varied from one time to another (P ϭ 0.008). Specifically, expression was significantly greater in thoracic wounds at week 3 (P ϭ 0.0028). SPARC mRNA expression was induced in both thoracic and limb wounds for the duration of the study; indeed, even after 6 wk of repair RT-PCR revealed a persistent induction in both locations (Fig. 3) .
Protein localization in healing thoracic and limb wounds. The immunoblot showed a specific band of the expected molecular weight (ϳ128 kDa) in equine adrenal cortex protein extract, confirming that the custom-made rabbit anti-equine THBS2 polyclonal antibody was specific for equine tissues. Immunoblotting, which showed a single band at 32 kDa, likewise confirmed the specificity of the commercial mouse anti-human SPARC monoclonal antibody in a protein extract of equine testis.
Immunohistochemical analysis was performed on normal intact skin and on 1, 2, 3, and 6 wk-old wound samples to document the presence of THBS2 protein (Table 1 ). In normal intact skin, constitutive expression was observed in the cells of the upper epidermis while the dermal compartment was devoid of stain (Fig. 4, A and B) . No differences were detected between thoracic and limb samples of normal intact skin, nor of wounds at either site.
In samples taken 1 wk following wounding, increased staining for THBS2 of the epidermis surrounding the wound was observed, especially in the suprabasal layers. In thoracic wounds, in which epithelialization had begun, the hyperplastic neo-formed epidermis was less reactive than the old one in adjacent intact skin (Fig. 4, C and D) . Some fibroblasts were weakly positive though no matrix-associated staining was observed. In wound edge samples obtained 2 wk postoperatively (Fig. 4, E and F) an increase in staining was observed in the neo-formed epidermis compared with what was observed at week 1. At 3 wk, immunostaining was similar to that observed at week 2, while 6 wk old samples, in which epithelialization was more advanced, showed a return to baseline conditions of the epidermal compartment. Cells of both the granulation tissue filling the wound bed and the dermis adjacent to the wound remained weakly positive throughout the study.
Cellular localization of SPARC protein in normal intact skin and wound tissues was determined by immunohistochemistry (Table 1 ). In normal intact skin, the epidermal compartment did not express the protein (Fig. 5, A and B) while some cells in the dermis, in particular those of sweat glands, hair papilla and vascular structures, showed strong cytoplasmic staining ( Fig. 5A, inset) . No immunoreactive signal was observed in the ECM and no qualitative differences in staining were detected between thoracic and limb intact skin.
While epithelialization was incomplete 1 wk following wounding, SPARC protein expression was clearly induced in the basal layers of the old epidermis adjacent to the wound margins (Fig. 5C ). The neoepidermis showed diffuse reactivity, particularly when hyperplastic (Fig. 5D) . Granulation tissue cells were strongly positive (Fig. 5D) . By 3 wk, wound epithelialization had progressed; consequently, more immunoreactivity was apparent although cellular localization of the protein was unchanged and no differences were noted between body and limb wounds (Fig. 5, E and F) .
DISCUSSION
The development of EGT and the consequent severe scarring of limb wounds in horses are related to an excessive proliferative phase where angiogenesis and fibroplasia are exacerbated (28, 36, 43) . Specifically, immunostaining for platelet endothelial adhesion molecule-1 (PECAM1 or CD31) documented a greater density of blood vessels within the granulation tissue of limb wounds compared with body wounds (31) . Thus, an imbalance between up-and downregulation of the molecular components governing angiogenesis during wound repair may underlie the abnormal healing pattern documented in the horse limb. A recent comprehensive study undertaken in our laboratory in an effort to identify the genes differentially expressed during normal wound repair in the horse showed an upregulation of THBS2 and SPARC (27) . While the generic function attributed to the matricellular proteins THBS2 and SPARC during wound repair is ECM remodeling, both have been assigned a more specific role as inhibitors of angiogenesis (11, 12, 17, 21, 26, 42, 45, 47) .
Equine THSB2 protein is highly conserved compared with that of other species. The 1,172 amino acids correspond to the total number observed in human (NP_003238) and mouse (AA016244) GenBank entries but exceed by two the bovine protein (NP_789861) and the predicted amino acid sequence deduced from the equine genomic sequence (XP_001915070). These differences, located at S 377 and A 378 of the herein characterized equine amino acid sequence (DQ976362), are positioned at the beginning of exon 7. Faulty positioning of the intron 6/exon 7 boundary in the genomic equine sequence yielded these two amino acids found in the cDNA sequence characterized from equine skin mRNA. Equine SPARC was also shown to be highly conserved compared with that of other species. In vertebrates, the SPARC protein encompasses three distinct modules (I, II, and III) (6) . Module I (A 3 -E 51 ) is encoded by exons 3 and 4, is highly acidic and binds 5- In the current study, THBS2 levels were significantly lower in limb compared with body wounds across time, compatible with the excessive development of vascularized granulation tissue present in wounds at the former location (28, 31, 43) .
Indeed, a previous study using this animal model demonstrated that delayed yet protracted inflammation, slow epithelialization, and deficient fibroblast orientation along with exaggerated angiogenesis/fibroplasia contribute to delays in healing of limb Table 1 . THBS2 and SPARC expression scores at the wound margin throughout the study
Immunohistochemical staining intensity for thrombospondin II (THBS2) and for secreted protein acidic and rich in cysteine (SPARC) proteins was scored as negative (Ϫ), weak (ϩ), moderate (ϩϩ), or strong (ϩϩϩ). T, thorax; L, limb; E, epidermal compartment; D, dermal compartment. wounds (28, 31) . Similarly, THBS2-null mice show a relative persistence of blood vessels through the later stages of repair of full-thickness excisional wounds compared with their wildtype counterparts (23) . In that study, the phase of vascular regression coincided with the peak expression of THBS2 protein.
While THBS2 mRNA expression in equine body wounds peaked at week 2, the time at which blood vessels begin disappearing in these wounds (28) , the immunohistochemical data from the present study are less straightforward. In fact, no differences were evident between body and limb wounds at any time, and immunostaining of the granulation tissue filling the wound beds did not visibly change over the 6 wk of the study despite obvious regression of angiogenesis in body wounds (28, 31) . Interestingly, a study performed in wild-type mice showed that despite an increase in THBS2 in wounds of aged wild-type mice, the vascular density of these wounds was not reduced compared with that in young animals (1), suggesting variations in the aforementioned correlation. Moreover, the temporal pattern of our immunohistochemical data may reflect the multiple roles of THBS2 in vivo, including its ability to regulate the influx of inflammatory cells into wounds (26) , such that continued presence of the protein might be a response to the chronic inflammation characteristic of horse wounds (28, 43) . Alternatively, incomplete correlation between mRNA and protein data may reflect the complex and varied mechanisms of posttranscriptional regulation during wound repair, which controls how mRNA is translated into protein (16) .
The spatial pattern of our THBS2 immunohistochemical data contrast with those of Kyriakides et al. (23) , who report positive staining only in the dermal compartment of 1-and 2-wk old wounds in mice. While staining of the epidermis might be nonspecific, as suggested by Bornstein et al. (4) , a recent study localized THBS2 mainly to the epithelial layer of healing mouse cornea (45) , suggesting that tissues other than those traditionally considered as possessing a substantial connective tissue component (reticular dermis, blood vessels, meninges, ligaments, pericardium, perichondrium, periosteum, and pleura) might also express the protein.
The late surge in THBS2 mRNA expression in body wounds documented herein is surprising, especially in view of the concomitant return to baseline in limb wounds. This might relate to the role of THBS2 in the regulation of collagen fibrillogenesis (21, 30) . As noted histologically (28) , body wounds remodel in a more timely fashion than do corresponding limb wounds, although 6 wk postwounding this process is still underway. It would be interesting to extend the study to document whether such a bimodal expression also occurs in limb wounds.
SPARC mRNA levels were significantly inferior in limb compared with body wounds only at postoperative week 3, which may or may not relate to its antiangiogenic effects. Perhaps more noteworthy is the persistent upregulation of SPARC mRNA in wounds from both locations for the duration of the study. We attribute this to the fact that 6 wk after their creation, excisional wounds in the horse have yet to completely heal. As a matricellular protein, SPARC enhances the permissiveness of ECM to cellular migration and differentiation and has been shown to induce the expression of MMPs in fibroblasts (40) . High levels of SPARC mRNA at the sixth week of repair are thus consistent with its proposed functions in remodeling, a process still active in equine wounds at this time, as shown in our previous studies using this model (28) .
Conversely, it is tempting to speculate that increased SPARC levels late in the repair process may contribute to the excessive scarring from which horses commonly suffer. To that effect, accelerated cutaneous wound closure (7) as well as a significant decrease in the thickness, the vascular density, and the size of collagen fibers of the foreign body capsule developing around subcutaneous implants (34) were reported in SPARC-null mice. In view of this, we expected to find comparatively greater expression of SPARC mRNA in limb wounds at the end of the study; this may occur beyond the 6 wk cut-off of our experiment, when SPARC levels in body wounds would return to baseline whereas high levels would be maintained in limb wounds which take longer to heal (19, 28, 43) .
While immunohistochemistry did not confirm a difference in SPARC protein expression between body and limb wounds, it did corroborate the mRNA data in that continued presence of the protein was detected in both the epidermal and dermal compartments 1 and 3 wk postoperatively. The persistent expression of SPARC protein through the mid-to-late stages of repair has been reported in full-thickness wounds of rats where immunohistochemistry identified reactive fibroblasts at the wound edge, consistent with SPARC's proposed functions in remodeling (35) . The localization of SPARC protein to the basal layers of the epidermis adjacent to the wound edge implies that it plays a role in epithelialization, possibly via modulation of keratinocyte adhesion, proliferation, and/or migration (6, 18) .
In conclusion, this study is the first to characterize equine cDNA for THBS2 and SPARC and to document that the genes for THBS2 and SPARC are expressed over the different phases of wound repair in horses. Since the protein structures resemble those of other species (10), it is more likely differences in their regulation that define the pattern of healing in distinct anatomical locations in the horse. The two molecules investigated herein have been attributed a number of roles, at times contradictory, depending on their cellular origin, their cellular target, and the physiological mechanisms in which they participate. Wound repair is a complex, dynamic process in which various cell populations interact in different manners during the healing phases. In vitro systems such as conventional two-dimensional cultures help elucidate the mechanisms underlying repair; however, for most studies making use of these models the question remains as to how far the results can be extrapolated to the in vivo situation. Thus, while data interpretation is a challenge, the value of our study lies in the fact that the findings are more representative of what truly occurs in the patient.
